NCT07145125View on ClinicalTrials.gov

Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2)

Not yet recruitingOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

November 30, 2025

Conditions

Relapsed or Refractory Hodgkin Lymphoma

Interventions

DRUG

Brentuximab-Vedotin associated with Bendamustine

Patient having received at least one course of the association Brentuximab-Vedotin and Bendamustine

Trial Locations (5)

Unknown

CH de la Côte Basque, service Hématologie Clinique, Bayonne

CHU de Bordeaux, service Hématologie Clinique et Thérapie cellulaire, Bordeaux

CHU de Caen, service Hématologie Clinique, Caen

Institut Paoli Calmettes, service Hématologie Clinique, Marseille

CHU de Toulouse, service Hématologie Clinique, Toulouse

All Listed Sponsors

lead

University Hospital, Bordeaux

OTHER

NCT07145125 - Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2) | Biotech Hunter | Biotech Hunter